<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00406393</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN0402</org_study_id>
    <secondary_id>U01HL069294</secondary_id>
    <secondary_id>BMT CTN 0402</secondary_id>
    <secondary_id>U01HL069294-05</secondary_id>
    <nct_id>NCT00406393</nct_id>
  </id_info>
  <brief_title>Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)</brief_title>
  <official_title>A Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus With Tacrolimus/Methotrexate as Graft-versus-Host Disease (GVHD) Prophylaxis After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation (BMT CTN #0402)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a phase III, randomized, open label, multicenter, prospective,
      comparative trial of sirolimus and tacrolimus versus tacrolimus and methotrexate as
      graft-versus-host disease (GVHD) prophylaxis after human leukocyte antigen (HLA)-matched,
      related, peripheral blood stem cell transplantation in individuals with hematologic cancer.
      Participants will be stratified by transplant center and will be randomly assigned to the
      sirolimus/tacrolimus or tacrolimus/methotrexate arms at a 1:1 ratio.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Stem cell transplantation is a standard therapy for acute and chronic leukemias and
      myelodysplastic disorders. A common problem that may occur after a stem cell transplant is a
      condition known as GVHD. The purpose of this study is to compare two combinations of
      medications to see which is better at preventing GVHD. The combinations of medications in
      this study are:

        -  Sirolimus and tacrolimus

        -  Methotrexate and tacrolimus

      Doctors want to know if one combination is better than the other or if they both have the
      same result.

      DESIGN NARRATIVE:

      Participants will receive one of the two conditioning regimens described in the protocol, at
      the discretion of the transplant physician. The transplant physician must choose among these
      regimens prior to the participant's assignment to the GVHD prophylaxis treatment.
      Conditioning regimens will vary by center, but will be the same for all participants at each
      center. Stem cell donors will donate peripheral blood stem cells according to local
      institutional practices. Peripheral blood stem cells will not be manipulated or T-depleted
      prior to administration. Standard post-transplant care will be administered. Participants
      will be randomly assigned to one of two GVHD prophylaxis regimens and will be followed for
      the endpoints of interest.

      Participants will be followed for 114 days post-randomization for evaluation of the primary
      endpoint, with additional follow-up for 2 years after transplantation for evaluation of
      secondary endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Grades II-IV Acute GVHD-free Survival</measure>
    <time_frame>Day 114</time_frame>
    <description>The primary objective is to compare rates of 114-day Grades II-IV acute GVHD-free survival post randomization for HLA-matched, related donor allogeneic peripheral blood stem cell transplantation using two different GVHD prophylaxis regimens. Participants are graded on a scale of 1 to 4 according to their symptoms and organs involved, where 4 represents a worse grade.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute GVHD</measure>
    <time_frame>Measured at Day 100</time_frame>
    <description>Cumulative incidence of acute GVHD (grade II-IV) occurring 100 days from transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Neutrophil and Platelet Engraftment</measure>
    <time_frame>Measured through Day 100</time_frame>
    <description>Neutrophil engraftment is defined as achieving an Absolute Neutrophil Count (ANC) &gt; 500/mcL for three consecutive measurements on different days. Platelet engraftment is defined as a platelet count &gt; 20,000/mcL for three consecutive measurements over three or more days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucositis Severity</measure>
    <time_frame>Measured at Day 21</time_frame>
    <description>Mucositis severity will be scored per the modified Oral Mucositis Assessment Scale (OMAS) scoring system on a scale of 0 - 4, where 0 equals normal mucosa and 4 represents severe mucosa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Veno-occlusive Disease (VOD)</measure>
    <time_frame>Measured through Day 100</time_frame>
    <description>VOD will be defined as the occurrence of VOD (based on the Baltimore Criteria for the diagnosis of VOD) in conjunction with other end-organ dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombotic Microangiopathy (TMA) Infection</measure>
    <time_frame>Measured through Day 100</time_frame>
    <description>The occurrence of TMA within the first 100 days after stem cell transplantation will be recorded. The first day of onset will be used for reporting purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactivation of Cytomegalovirus (CMV) Infection</measure>
    <time_frame>Measured at Year 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related Mortality</measure>
    <time_frame>Measured at Day 100 and Year 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignant Disease Relapse</measure>
    <time_frame>Measured at Year 2</time_frame>
    <description>Testing for recurrent malignancy in the blood, marrow or other sites will be used to assess relapse after transplantation. For the purpose of this study, relapse is defined by either morphological or cytogenetic evidence of AML, ALL, CML, MDS or CMML consistent with pre-transplant features.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Measured at Year 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>Measured at Year 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge After Transplant</measure>
    <time_frame>Measured at Year 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Leukemia, Myelocytic, Acute</condition>
  <condition>Leukemia, Lymphocytic, Acute</condition>
  <condition>Leukemia, Myeloid, Chronic</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Tacrolimus/Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus/Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.
The target serum level for tacrolimus is 5-10 ng/mL.</description>
    <arm_group_label>Tacrolimus/Methotrexate</arm_group_label>
    <arm_group_label>Tacrolimus/Sirolimus</arm_group_label>
    <other_name>PrografÂ®</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.</description>
    <arm_group_label>Tacrolimus/Methotrexate</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Adults: Sirolimus will be given in a loading dose of 12 mg on Day -3 followed by a daily oral dose of 4 mg per day. Doses may be repeated if the subject vomits within 15 minutes of an oral dose.
Children: Children aged &lt; 12.0 years OR weighing &lt; 40.0 kg will be given an oral loading dose of sirolimus of 3 mg/m2 followed by a daily oral dose of 1 mg/m2, rounded to the nearest full milligram.
The target serum level for sirolimus is 3-12 ng/mL.</description>
    <arm_group_label>Tacrolimus/Sirolimus</arm_group_label>
    <other_name>Rapamycin</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6/6 HLA-matched sibling, defined by Class I (HLA-A and B) serologic typing (or higher
             resolution) and Class II (HLA-DRBI) molecular typing, who is willing to donate
             peripheral blood stem cells, and meets institutional criteria for stem cell donation.
             The donor must be medically eligible to donate stem cells, according to individual
             transplant center criteria. Pediatric patients for whom a pediatric sibling donor is
             not anticipated to be a suitable leukapheresis candidate are not eligible.

          -  Karnofsky performance status of at least 70% or Lansky performance status of at least
             70% for participants less than 16 years old

          -  For participants less than 18 years old, willing and able to take oral medications,
             per the treating physician's recommendations

        Exclusion Criteria:

          -  Prior allogeneic or autologous transplant using any hematopoietic stem cell source

          -  Seropositive for the human immunodeficiency virus (HIV)

          -  Uncontrolled bacterial, viral, or fungal infection (currently taking medication and
             progression of clinical symptoms)

          -  Pregnant (positive serum human chorionic gonadotropin [Î²-HCG] test) or breastfeeding
             within 4 weeks of study entry

          -  Kidney function: serum creatinine outside the normal range for age, or measured
             creatinine clearance less than 50 mL/min/1.72m^2 within 4 weeks of study entry

          -  Liver function: most recent direct bilirubin, alanine aminotransferase (ALT), or
             aspartate aminotransferase (AST) greater than two times the upper limit of normal
             within 4 weeks of study entry

          -  Lung disease: in adults, forced vital capacity (FVC) or forced expiratory volume in
             one second (FEV1) less than 60% of predicted value (corrected for hemoglobin); in
             children, overt hypoxemia, as measured by an oxygen saturation of less than 92% within
             4 weeks of study entry

          -  Cardiac ejection fraction of less than 45% in adults and children, or less than 26%
             shortening fraction in children within 4 weeks of study entry

          -  Cholesterol level greater than 500 mg/dL or triglyceride level greater than 500 mg/dL
             while being treated, or not on appropriate lipid-lowering therapy within 4 weeks of
             study entry

          -  Prior history of allergy to sirolimus

          -  Requires voriconazole at time of study entry

          -  Currently receiving another investigational drug unless cleared by the protocol
             officer or protocol chair

          -  Participants with a history of cancer, other than resected basal cell carcinoma or
             treated carcinoma in-situ. Cancer treated with curative intent for more than 5 years
             previously will be allowed. Cancer treated with curative intent for less than 5 years
             previously will not be allowed unless approved by the protocol officer or protocol
             chair.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>LaJolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine (Shands)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DFCI/Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland/Case Western</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State, Arthur G. James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/MCV Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital &amp; Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-5156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>CEDEX 10</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net</url>
    <description>Blood and Marrow Transplant Clinical Trials Network</description>
  </link>
  <results_reference>
    <citation>Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, Hogan WJ, Pasquini M, MacMillan ML, Hsu JW, Waller EK, Grupp S, McCarthy P, Wu J, Hu ZH, Carter SL, Horowitz MM, Antin JH. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014 Aug 21;124(8):1372-7. doi: 10.1182/blood-2014-04-567164. Epub 2014 Jun 30.</citation>
    <PMID>24982504</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2006</study_first_submitted>
  <study_first_submitted_qc>November 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <results_first_submitted>January 6, 2016</results_first_submitted>
  <results_first_submitted_qc>February 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2016</results_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Chronic Myelogenous Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Findings will be published in a manuscript.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 2006 to 2011 from 24 different transplant centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tacrolimus/Sirolimus</title>
          <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
        </group>
        <group group_id="P2">
          <title>Tacrolimus/Methotrexate</title>
          <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not undergo transplantation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tacrolimus/Sirolimus</title>
          <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
        </group>
        <group group_id="B2">
          <title>Tacrolimus/Methotrexate</title>
          <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="304"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="19" upper_limit="59"/>
                    <measurement group_id="B2" value="43" lower_limit="13" upper_limit="58"/>
                    <measurement group_id="B3" value="44" lower_limit="13" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Acute Myelogenous Leukemia (AML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Lymphoblastic Leukemia (ALL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Myelogenous Leukemia (CML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myelodysplastic Syndrome (MDS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Biphenotypic Leukemia (ABL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Status at Transplantation</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>AML 1st Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AML 2nd Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALL 1st Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALL 2nd Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CML 1st Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CML 2nd Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABL 1st Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Score</title>
          <description>Assesses patient self-perceived global quality of life and functioning (excellent, very good, good, fair, poor), where 100 equals perfect quality of life.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Scores 90 - 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scores &lt; 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recipient-Donor Cytomegalovirus Status</title>
          <description>Seropositivity (+) or Seronegativity (-) for the recipient / Seropositivity (+) or Seronegativity (-) for the donor</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>+/+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+/-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-/+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-/-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conditioning Regimen</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Cyclophosphamide/Total Body Irradiation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Etoposide/Total Body Irradiation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Grades II-IV Acute GVHD-free Survival</title>
        <description>The primary objective is to compare rates of 114-day Grades II-IV acute GVHD-free survival post randomization for HLA-matched, related donor allogeneic peripheral blood stem cell transplantation using two different GVHD prophylaxis regimens. Participants are graded on a scale of 1 to 4 according to their symptoms and organs involved, where 4 represents a worse grade.</description>
        <time_frame>Day 114</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/Sirolimus</title>
            <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus/Methotrexate</title>
            <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Grades II-IV Acute GVHD-free Survival</title>
          <description>The primary objective is to compare rates of 114-day Grades II-IV acute GVHD-free survival post randomization for HLA-matched, related donor allogeneic peripheral blood stem cell transplantation using two different GVHD prophylaxis regimens. Participants are graded on a scale of 1 to 4 according to their symptoms and organs involved, where 4 represents a worse grade.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="59" upper_limit="74"/>
                    <measurement group_id="O2" value="62" lower_limit="54" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Acute GVHD</title>
        <description>Cumulative incidence of acute GVHD (grade II-IV) occurring 100 days from transplantation.</description>
        <time_frame>Measured at Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/Sirolimus</title>
            <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus/Methotrexate</title>
            <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute GVHD</title>
          <description>Cumulative incidence of acute GVHD (grade II-IV) occurring 100 days from transplantation.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="19" upper_limit="34"/>
                    <measurement group_id="O2" value="34" lower_limit="26" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Neutrophil and Platelet Engraftment</title>
        <description>Neutrophil engraftment is defined as achieving an Absolute Neutrophil Count (ANC) &gt; 500/mcL for three consecutive measurements on different days. Platelet engraftment is defined as a platelet count &gt; 20,000/mcL for three consecutive measurements over three or more days.</description>
        <time_frame>Measured through Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/Sirolimus</title>
            <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus/Methotrexate</title>
            <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Neutrophil and Platelet Engraftment</title>
          <description>Neutrophil engraftment is defined as achieving an Absolute Neutrophil Count (ANC) &gt; 500/mcL for three consecutive measurements on different days. Platelet engraftment is defined as a platelet count &gt; 20,000/mcL for three consecutive measurements over three or more days.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutrophil Engraftment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="8" upper_limit="27"/>
                    <measurement group_id="O2" value="16" lower_limit="10" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Engraftment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="7" upper_limit="100"/>
                    <measurement group_id="O2" value="19" lower_limit="9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mucositis Severity</title>
        <description>Mucositis severity will be scored per the modified Oral Mucositis Assessment Scale (OMAS) scoring system on a scale of 0 - 4, where 0 equals normal mucosa and 4 represents severe mucosa.</description>
        <time_frame>Measured at Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/Sirolimus</title>
            <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus/Methotrexate</title>
            <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mucositis Severity</title>
          <description>Mucositis severity will be scored per the modified Oral Mucositis Assessment Scale (OMAS) scoring system on a scale of 0 - 4, where 0 equals normal mucosa and 4 represents severe mucosa.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.28"/>
                    <measurement group_id="O2" value="0.47" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Veno-occlusive Disease (VOD)</title>
        <description>VOD will be defined as the occurrence of VOD (based on the Baltimore Criteria for the diagnosis of VOD) in conjunction with other end-organ dysfunction.</description>
        <time_frame>Measured through Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/Sirolimus</title>
            <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus/Methotrexate</title>
            <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Veno-occlusive Disease (VOD)</title>
          <description>VOD will be defined as the occurrence of VOD (based on the Baltimore Criteria for the diagnosis of VOD) in conjunction with other end-organ dysfunction.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="6" upper_limit="16"/>
                    <measurement group_id="O2" value="5" lower_limit="2" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thrombotic Microangiopathy (TMA) Infection</title>
        <description>The occurrence of TMA within the first 100 days after stem cell transplantation will be recorded. The first day of onset will be used for reporting purposes.</description>
        <time_frame>Measured through Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/Sirolimus</title>
            <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus/Methotrexate</title>
            <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombotic Microangiopathy (TMA) Infection</title>
          <description>The occurrence of TMA within the first 100 days after stem cell transplantation will be recorded. The first day of onset will be used for reporting purposes.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reactivation of Cytomegalovirus (CMV) Infection</title>
        <time_frame>Measured at Year 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/Sirolimus</title>
            <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus/Methotrexate</title>
            <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Reactivation of Cytomegalovirus (CMV) Infection</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="9" upper_limit="19"/>
                    <measurement group_id="O2" value="15" lower_limit="10" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-related Mortality</title>
        <time_frame>Measured at Day 100 and Year 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/Sirolimus</title>
            <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus/Methotrexate</title>
            <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Mortality</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3" upper_limit="11"/>
                    <measurement group_id="O2" value="7" lower_limit="4" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="13" upper_limit="26"/>
                    <measurement group_id="O2" value="16" lower_limit="11" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Malignant Disease Relapse</title>
        <description>Testing for recurrent malignancy in the blood, marrow or other sites will be used to assess relapse after transplantation. For the purpose of this study, relapse is defined by either morphological or cytogenetic evidence of AML, ALL, CML, MDS or CMML consistent with pre-transplant features.</description>
        <time_frame>Measured at Year 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/Sirolimus</title>
            <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus/Methotrexate</title>
            <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Malignant Disease Relapse</title>
          <description>Testing for recurrent malignancy in the blood, marrow or other sites will be used to assess relapse after transplantation. For the purpose of this study, relapse is defined by either morphological or cytogenetic evidence of AML, ALL, CML, MDS or CMML consistent with pre-transplant features.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="20" upper_limit="35"/>
                    <measurement group_id="O2" value="29" lower_limit="22" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>Measured at Year 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/Sirolimus</title>
            <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus/Methotrexate</title>
            <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="51" upper_limit="67"/>
                    <measurement group_id="O2" value="63" lower_limit="55" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infections</title>
        <time_frame>Measured at Year 2</time_frame>
        <population>Insufficient data to report on this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/Sirolimus</title>
            <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus/Methotrexate</title>
            <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Infections</title>
          <population>Insufficient data to report on this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discharge After Transplant</title>
        <time_frame>Measured at Year 2</time_frame>
        <population>Insufficient data to report on this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus/Sirolimus</title>
            <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus/Methotrexate</title>
            <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discharge After Transplant</title>
          <population>Insufficient data to report on this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2-years post transplant</time_frame>
      <desc>Serious adverse events are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tacrolimus/Sirolimus</title>
          <description>Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.</description>
        </group>
        <group group_id="E2">
          <title>Tacrolimus/Methotrexate</title>
          <description>Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Thoracotomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Mendizabal, PhD</name_or_title>
      <organization>The Emmes Corporation</organization>
      <phone>301-251-1161</phone>
      <email>amendizabal@emmes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

